New drug cocktail shows promise for Tough-to-Treat blood cancer

This study tested a combination of three drugs (ibrutinib, fludarabine, and pembrolizumab) in 15 people with high-risk or relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see if the combination could achieve a complete response, meaning no signs of cancer. Participants received ibrutinib continuously, a short course of fludarabine, and pembrolizumab every three weeks for a year. The study is completed, and results help understand how well this approach works for hard-to-treat CLL.